Lonza Signs Exclusive Deal with Qurient to Advance Dual-Payload ADC Cancer Therapies

Dual-payload antibody-drug conjugates introduce compounding containment and process validation demands that most CDMO platforms are not yet equipped to handle at commercial scale, and Lonza's exclusive agreement with South Korean oncology firm Qurient positions the Swiss contract manufacturer to close that gap ahead of the field.

Under the agreement, Lonza will apply its proprietary ADC technology platform to support Qurient's pipeline of dual-payload conjugates targeting cancer. The deal is structured as an exclusive arrangement, giving Lonza preferential access to Qurient's next-generation programs while extending its own technology reach beyond conventional single-payload ADC formats. Financial terms were not disclosed.

For plant heads and QA directors, the operational weight of dual-payload ADC manufacturing is non-trivial. Each additional cytotoxic payload compounds the high-potency active pharmaceutical ingredient (HPAPI) containment requirements, typically demanding occupational exposure band (OEB) 4 or 5 facilities, segregated processing suites, and validated cleaning procedures that satisfy both 21 CFR Part 211 and EMA expectations. Process validation packages must account for conjugation efficiency across two distinct linker-payload chemistries, adding analytical complexity to release testing and in-process controls.

The agreement also reflects a broader competitive shift in the CDMO sector. As drug developers move toward structurally complex biologics, bispecific antibodies, dual-payload ADCs, conditionally activated constructs, manufacturing partners are under pressure to demonstrate platform flexibility without compromising sterility assurance or batch consistency. Lonza's move signals that proprietary technology licensing, not just capacity, is becoming a primary differentiator in CDMO contract negotiations.

For regulatory affairs leads, the dual-payload architecture raises questions around comparability protocols and how changes to either payload's conjugation chemistry will be handled under ICH Q10 pharmaceutical quality system frameworks, particularly if post-approval manufacturing changes are required.

The pace at which Lonza integrates Qurient's programs into validated production workflows, and the agency interactions that follow, will serve as an early indicator of how dual-payload ADC manufacturing scales under current GMP expectations.

Source: Media4Growth via Indian Pharma Post, 12 October 2026.